ShuimuBio is an evolving cryo-EM & AI platform empowering faster drug discovery via harnessing structural insights of difficult-to-crystallize biological targets.
Leverage cryo-EM & AI to accelerate and push the boundaries of modern-day drug discovery.
“Biochemical maps have long been filled with blank spaces because the available technology has had difficulty generating images of much of life‘s molecular machinery. Cryo-electron microscopy changes all of this.” Cryo-EM is revealing structures of medically relevant biomolecules at an ever-increasing pace, reshaping the drug discovery landscape. By integrating AI into the process of cryo-EM-enabled drug discovery, we are dramatically accelerating early drug R&D.
See unseeable. Drug undruggable.
Most of the validated biological molecule targets of next-generation drugs such as transmembrane receptors (e.g., GPCRs) and dynamic complexes are proteins notoriously difficult to crystallize, raising a high bar for scientists to obtain their structures through the traditional crystallography method. Our advanced 300kV cryo-EM platform opens the door to many of these targets, acquiring their structures at near-atomic resolution, and thus turning them into seeable and druggable targets.
Boost structure accuracy and resolution via top-notch AI.
A high-accuracy molecule structure model of the biological target at atomic resolution is critical to a successful structure-based drug discovery effort. While a seasoned structure biologist is capable of constructing reasonably reliable structures, structure determination is still a complex task and humans have limitations. We are incorporating deep learning to rapidly improve model accuracy and map resolution.
Speed up everything with ShuimuBio powered cryo-EM computing platform.
As cryo-EM quickly becomes the most preferred technology for structural characterization and candidate screening, the throughput is required to facilitate faster drug discovery. We are dedicated to providing the most powerful cryo-EM computing platform in the world, making high-throughput cryo-EM a new norm. During the Omicron outbreak, dozens of Omicron antigen-antibody complex structures have been successfully resolved by us (highest resolution at 2.5Å) within a few days.
Be the first, not the better.
We are ready to team up with aspiring partners who are determined to bring first-in-class drugs and pioneer neo therapies to the world. Combining Cryo-EM and AI technology, we make the previously impossible ideas possible. “It is very easy to answer many fundamental biological questions: you just look at the thing.” Let's unveil the mysteries and make the most impactful breakthroughs.
Case Study: Cryo-EM Enabled Conformational Epitope Mapping Inspires Novel and Highly Differentiated Antibody Development
Shuimu BioSciences will hold booth#2013 during the AACR 2022 event
Serial Entrepreneur Allen Guo: Go Beyond Boundaries
NEXT TECH Opens, Shuimu BioSciences Helping French Pharmaceutical Companies to Innovate in China
CONTACT
SHUIMUBIO
Hi@shuimubio.com
+ 86 18510728199
B1,National Institute of Biological Sciences，
Changping Beijing, PR China
